{"pmid":32379896,"title":"Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs.","text":["Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs.","The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 a pandemic. There is, however, no confirmed anti-COVID-19 therapeutic currently. In order to assist structure-based discovery efforts for repurposing drugs against this disease, we constructed knowledge-based models of SARS-CoV-2 proteins and compared the ligand molecules in the template structures with approved/experimental drugs and components of natural medicines. Our theoretical models suggest several drugs, such as carfilzomib, sinefungin, tecadenoson, and trabodenoson, that could be further investigated for their potential for treating COVID-19.","FEBS Lett","Hijikata, Atsushi","Shionyu-Mitsuyama, Clara","Nakae, Setsu","Shionyu, Masafumi","Ota, Motonori","Kanaya, Shigehiko","Shirai, Tsuyoshi","32379896"],"abstract":["The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 a pandemic. There is, however, no confirmed anti-COVID-19 therapeutic currently. In order to assist structure-based discovery efforts for repurposing drugs against this disease, we constructed knowledge-based models of SARS-CoV-2 proteins and compared the ligand molecules in the template structures with approved/experimental drugs and components of natural medicines. Our theoretical models suggest several drugs, such as carfilzomib, sinefungin, tecadenoson, and trabodenoson, that could be further investigated for their potential for treating COVID-19."],"journal":"FEBS Lett","authors":["Hijikata, Atsushi","Shionyu-Mitsuyama, Clara","Nakae, Setsu","Shionyu, Masafumi","Ota, Motonori","Kanaya, Shigehiko","Shirai, Tsuyoshi"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379896","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/1873-3468.13806","keywords":["covid-19","coronavirus","sars-cov","crude drug","drug repurposing","homology modeling"],"e_drugs":["carfilzomib","sinefungin","tecadenoson","trabodenoson"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097267265536,"score":9.490897,"similar":[{"pmid":32292689,"pmcid":"PMC7102550","title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","text":["Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.","Acta Pharm Sin B","Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua","32292689"],"abstract":["SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections."],"journal":"Acta Pharm Sin B","authors":["Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292689","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.apsb.2020.02.008","keywords":["3clpro, 3-chymotrypsin-like protease","drug repurposing","e, envelope","homology modeling","m, membrane protein","molecular docking","n, nucleocapsid protein","nsp, non-structure protein","orf, open reading frame","pdb, protein data bank","rdrp, rna-dependence rna polymerase","remdesivir","s, spike","sars-cov-2","sud, sars unique domain","ub, ubiquitin-like domain"],"topics":["Treatment"],"weight":1,"_version_":1666138494492213249,"score":235.09988},{"pmid":32181901,"title":"A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","text":["A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV were found. In this study, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is a critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design.","J Med Virol","Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen","32181901"],"abstract":["During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV were found. In this study, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is a critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design."],"journal":"J Med Virol","authors":["Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181901","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25768","keywords":["2019-ncov","blast algorithm","clustal analysis","mers-cov","sars-cov","coronavirus","homology modeling","sequence alignment"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666138490585219072,"score":198.6542},{"pmid":32488835,"pmcid":"PMC7266118","title":"Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.","text":["Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.","A novel coronavirus, called 2019-nCoV, was recently found in Wuhan, Hubei Province of China, and now is spreading across China and other parts of the world. Although there are some drugs to treat 2019-nCoV, there is no proper scientific evidence about its activity on the virus. It is of high significance to develop a drug that can combat the virus effectively to save valuable human lives. It usually takes a much longer time to develop a drug using traditional methods. For 2019-nCoV, it is now better to rely on some alternative methods such as deep learning to develop drugs that can combat such a disease effectively since 2019-nCoV is highly homologous to SARS-CoV. In the present work, we first collected virus RNA sequences of 18 patients reported to have 2019-nCoV from the public domain database, translated the RNA into protein sequences, and performed multiple sequence alignment. After a careful literature survey and sequence analysis, 3C-like protease is considered to be a major therapeutic target and we built a protein 3D model of 3C-like protease using homology modeling. Relying on the structural model, we used a pipeline to perform large scale virtual screening by using a deep learning based method to accurately rank/identify protein-ligand interacting pairs developed recently in our group. Our model identified potential drugs for 2019-nCoV 3C-like protease by performing drug screening against four chemical compound databases (Chimdiv, Targetmol-Approved_Drug_Library, Targetmol-Natural_Compound_Library, and Targetmol-Bioactive_Compound_Library) and a database of tripeptides. Through this paper, we provided the list of possible chemical ligands (Meglumine, Vidarabine, Adenosine, D-Sorbitol, D-Mannitol, Sodium_gluconate, Ganciclovir and Chlorobutanol) and peptide drugs (combination of isoleucine, lysine and proline) from the databases to guide the experimental scientists and validate the molecules which can combat the virus in a shorter time.","Interdiscip Sci","Zhang, Haiping","Saravanan, Konda Mani","Yang, Yang","Hossain, Md Tofazzal","Li, Junxin","Ren, Xiaohu","Pan, Yi","Wei, Yanjie","32488835"],"abstract":["A novel coronavirus, called 2019-nCoV, was recently found in Wuhan, Hubei Province of China, and now is spreading across China and other parts of the world. Although there are some drugs to treat 2019-nCoV, there is no proper scientific evidence about its activity on the virus. It is of high significance to develop a drug that can combat the virus effectively to save valuable human lives. It usually takes a much longer time to develop a drug using traditional methods. For 2019-nCoV, it is now better to rely on some alternative methods such as deep learning to develop drugs that can combat such a disease effectively since 2019-nCoV is highly homologous to SARS-CoV. In the present work, we first collected virus RNA sequences of 18 patients reported to have 2019-nCoV from the public domain database, translated the RNA into protein sequences, and performed multiple sequence alignment. After a careful literature survey and sequence analysis, 3C-like protease is considered to be a major therapeutic target and we built a protein 3D model of 3C-like protease using homology modeling. Relying on the structural model, we used a pipeline to perform large scale virtual screening by using a deep learning based method to accurately rank/identify protein-ligand interacting pairs developed recently in our group. Our model identified potential drugs for 2019-nCoV 3C-like protease by performing drug screening against four chemical compound databases (Chimdiv, Targetmol-Approved_Drug_Library, Targetmol-Natural_Compound_Library, and Targetmol-Bioactive_Compound_Library) and a database of tripeptides. Through this paper, we provided the list of possible chemical ligands (Meglumine, Vidarabine, Adenosine, D-Sorbitol, D-Mannitol, Sodium_gluconate, Ganciclovir and Chlorobutanol) and peptide drugs (combination of isoleucine, lysine and proline) from the databases to guide the experimental scientists and validate the molecules which can combat the virus in a shorter time."],"journal":"Interdiscip Sci","authors":["Zhang, Haiping","Saravanan, Konda Mani","Yang, Yang","Hossain, Md Tofazzal","Li, Junxin","Ren, Xiaohu","Pan, Yi","Wei, Yanjie"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32488835","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s12539-020-00376-6","keywords":["3c-like protease","coronavirus","deep learning","drug screening","homology modeling"],"locations":["Wuhan","China","Adenosine"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Adenosine"],"topics":["Treatment"],"weight":1,"_version_":1668892169265479680,"score":177.15404},{"pmid":32306822,"title":"Peptide-like and small-molecule inhibitors against Covid-19.","text":["Peptide-like and small-molecule inhibitors against Covid-19.","Coronavirus disease strain (SARS-CoV-2) was discovered in 2019, and it is spreading very fast around the world causing the disease Covid-19. Currently, more than 1.6 million individuals are infected, and several thousand are dead across the globe because of Covid-19. Here, we utilized the in-silico approaches to identify possible protease inhibitors against SARS-CoV-2. Potential compounds were screened from the CHEMBL database, ZINC database, FDA approved drugs and molecules under clinical trials. Our study is based on 6Y2F and 6W63 co-crystallized structures available in the protein data bank (PDB). Seven hundred compounds from ZINC/CHEMBL databases and fourteen hundred compounds from drug-bank were selected based on positive interactions with the reported binding site. All the selected compounds were subjected to standard-precision (SP) and extra-precision (XP) mode of docking. Generated docked poses were carefully visualized for known interactions within the binding site. Molecular mechanics-generalized born surface area (MM-GBSA) calculations were performed to screen the best compounds based on docking scores and binding energy values. Molecular dynamics (MD) simulations were carried out on four selected compounds from the CHEMBL database to validate the stability and interactions. MD simulations were also performed on the PDB structure 6YF2F to understand the differences between screened molecules and co-crystallized ligand. We screened 300 potential compounds from various databases, and 66 potential compounds from FDA approved drugs. Cobicistat, ritonavir, lopinavir, and darunavir are in the top screened molecules from FDA approved drugs. The screened drugs and molecules may be helpful in fighting with SARS-CoV-2 after further studies.","J Biomol Struct Dyn","Pant, Suyash","Singh, Meenakshi","Ravichandiran, V","Murty, U S N","Srivastava, Hemant Kumar","32306822"],"abstract":["Coronavirus disease strain (SARS-CoV-2) was discovered in 2019, and it is spreading very fast around the world causing the disease Covid-19. Currently, more than 1.6 million individuals are infected, and several thousand are dead across the globe because of Covid-19. Here, we utilized the in-silico approaches to identify possible protease inhibitors against SARS-CoV-2. Potential compounds were screened from the CHEMBL database, ZINC database, FDA approved drugs and molecules under clinical trials. Our study is based on 6Y2F and 6W63 co-crystallized structures available in the protein data bank (PDB). Seven hundred compounds from ZINC/CHEMBL databases and fourteen hundred compounds from drug-bank were selected based on positive interactions with the reported binding site. All the selected compounds were subjected to standard-precision (SP) and extra-precision (XP) mode of docking. Generated docked poses were carefully visualized for known interactions within the binding site. Molecular mechanics-generalized born surface area (MM-GBSA) calculations were performed to screen the best compounds based on docking scores and binding energy values. Molecular dynamics (MD) simulations were carried out on four selected compounds from the CHEMBL database to validate the stability and interactions. MD simulations were also performed on the PDB structure 6YF2F to understand the differences between screened molecules and co-crystallized ligand. We screened 300 potential compounds from various databases, and 66 potential compounds from FDA approved drugs. Cobicistat, ritonavir, lopinavir, and darunavir are in the top screened molecules from FDA approved drugs. The screened drugs and molecules may be helpful in fighting with SARS-CoV-2 after further studies."],"journal":"J Biomol Struct Dyn","authors":["Pant, Suyash","Singh, Meenakshi","Ravichandiran, V","Murty, U S N","Srivastava, Hemant Kumar"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306822","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1080/07391102.2020.1757510","keywords":["covid-19","drug repurposing","md simulations","virtual screening"],"e_drugs":["Ritonavir","Lopinavir","Cobicistat","Darunavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491238481920,"score":167.79956},{"pmid":32462970,"title":"Identification of Potential Inhibitors of SARS-COV-2 Endoribonuclease (EndoU) from FDA Approved Drugs: A Drug Repurposing Approach to find Therapeutics for COID19.","text":["Identification of Potential Inhibitors of SARS-COV-2 Endoribonuclease (EndoU) from FDA Approved Drugs: A Drug Repurposing Approach to find Therapeutics for COID19.","SARS-CoV-2 is causative agent of COVID 19, which is responsible for severe social and economic disruption globally. Lack of vaccine or antiviral drug with clinical efficacy suggested that drug repurposing approach may provide a quick therapeutic solution to COVID19. Nonstructural Protein-15 (NSP15) encodes for an uridylate-specific endoribonuclease (EndoU) enzyme, essential for virus life cycle and an attractive target for drug development. We have performed in silico based virtual screening of FDA approved compounds targeting EndoU in search of COVID19 drugs from commercially available approved molecules. Two drugs Glisoxepide and Idarubicin used for treatment for diabetes and leukemia respectively were selected as stronger binder of EndoU. Both the drugs bound to the active site of the viral endonuclease by forming attractive intermolecular interactions with catalytically essential amino acid residues, His235, His250 and Lys290. Molecular dynamics simulation studies showed stable conformation dynamics upon drugs binding to endoU. The binding free energies for Glisoxepide and Idarubicin were calculated to be -141 +/- 11 and -136 +/- 16 kJ/mol respectively. The IC50 were predicted to be 9.2microM and 30microM for Glisoxepide and Idarubicin respectively. Comparative structural analysis showed the stronger binding of EndoU to Glisoxepide and Idarubicin than uridine monophosphate (UMP). Surface area calculations showed buried are of 361.8A(2) by Glisoxepide which is almost double of the area occupied by UMP suggesting stronger binding of the drug than the ribonucleotide. However, further studies on these drugs for evaluation of their clinical efficacy and dose formulations may be required, which may provide a quick therapeutic option to treat COVID-19.Abbreviation: COVID-19: Coronavirus Disease 2019; PCA: Principal Component Analysis; MD: Molecular Dynamics; MM/PBSA: Molecular Mechanics Poisson-Boltzmann Surface Area; nCoV: Novel Coronavirus; PME: Particle-Mesh Ewald; RMSD: Root Mean Square Deviations; RMSF: Root Mean Square Fluctuations; SARS-CoV-2: Severe Acute Respiratory Syndrome-Coronavirus-2; SASA: Solvent Accessible Surface Area; SPC: Simple Point Charge.","J Biomol Struct Dyn","Chandra, Anshuman","Gurjar, Vaishali","Qamar, Imteyaz","Singh, Nagendra","32462970"],"abstract":["SARS-CoV-2 is causative agent of COVID 19, which is responsible for severe social and economic disruption globally. Lack of vaccine or antiviral drug with clinical efficacy suggested that drug repurposing approach may provide a quick therapeutic solution to COVID19. Nonstructural Protein-15 (NSP15) encodes for an uridylate-specific endoribonuclease (EndoU) enzyme, essential for virus life cycle and an attractive target for drug development. We have performed in silico based virtual screening of FDA approved compounds targeting EndoU in search of COVID19 drugs from commercially available approved molecules. Two drugs Glisoxepide and Idarubicin used for treatment for diabetes and leukemia respectively were selected as stronger binder of EndoU. Both the drugs bound to the active site of the viral endonuclease by forming attractive intermolecular interactions with catalytically essential amino acid residues, His235, His250 and Lys290. Molecular dynamics simulation studies showed stable conformation dynamics upon drugs binding to endoU. The binding free energies for Glisoxepide and Idarubicin were calculated to be -141 +/- 11 and -136 +/- 16 kJ/mol respectively. The IC50 were predicted to be 9.2microM and 30microM for Glisoxepide and Idarubicin respectively. Comparative structural analysis showed the stronger binding of EndoU to Glisoxepide and Idarubicin than uridine monophosphate (UMP). Surface area calculations showed buried are of 361.8A(2) by Glisoxepide which is almost double of the area occupied by UMP suggesting stronger binding of the drug than the ribonucleotide. However, further studies on these drugs for evaluation of their clinical efficacy and dose formulations may be required, which may provide a quick therapeutic option to treat COVID-19.Abbreviation: COVID-19: Coronavirus Disease 2019; PCA: Principal Component Analysis; MD: Molecular Dynamics; MM/PBSA: Molecular Mechanics Poisson-Boltzmann Surface Area; nCoV: Novel Coronavirus; PME: Particle-Mesh Ewald; RMSD: Root Mean Square Deviations; RMSF: Root Mean Square Fluctuations; SARS-CoV-2: Severe Acute Respiratory Syndrome-Coronavirus-2; SASA: Solvent Accessible Surface Area; SPC: Simple Point Charge."],"journal":"J Biomol Struct Dyn","authors":["Chandra, Anshuman","Gurjar, Vaishali","Qamar, Imteyaz","Singh, Nagendra"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462970","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/07391102.2020.1775127","keywords":["binding affinity","drug repurposing","endonuclease","ic50","molecular dynamic simulation","sars-cov-2"],"e_drugs":["Amino Acids, Essential","Uridine Monophosphate","Ribonucleotides","glisoxepide","Idarubicin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521291567104,"score":165.26288}]}